ITUB20160876A1 - Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo - Google Patents

Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Info

Publication number
ITUB20160876A1
ITUB20160876A1 ITUB2016A000876A ITUB20160876A ITUB20160876A1 IT UB20160876 A1 ITUB20160876 A1 IT UB20160876A1 IT UB2016A000876 A ITUB2016A000876 A IT UB2016A000876A IT UB20160876 A ITUB20160876 A IT UB20160876A IT UB20160876 A1 ITUB20160876 A1 IT UB20160876A1
Authority
IT
Italy
Prior art keywords
miopia
arrest
man
prevention
combination
Prior art date
Application number
ITUB2016A000876A
Other languages
English (en)
Inventor
Enzo Maria D'ambrosio
Original Assignee
Dambrosio Enzo Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dambrosio Enzo Maria filed Critical Dambrosio Enzo Maria
Priority to ITUB2016A000876A priority Critical patent/ITUB20160876A1/it
Priority to PCT/EP2017/053619 priority patent/WO2017140846A1/en
Priority to SG11201806599SA priority patent/SG11201806599SA/en
Priority to KR1020187026872A priority patent/KR20180117642A/ko
Priority to CN201780011993.4A priority patent/CN108883060A/zh
Priority to CA3013846A priority patent/CA3013846A1/en
Priority to US15/999,784 priority patent/US20200253951A1/en
Priority to JP2018543132A priority patent/JP2019505542A/ja
Priority to AU2017220640A priority patent/AU2017220640B2/en
Priority to BR112018016845A priority patent/BR112018016845A2/pt
Priority to EP17710482.5A priority patent/EP3416617A1/en
Priority to RU2018133026A priority patent/RU2793238C2/ru
Priority to SG10202007417SA priority patent/SG10202007417SA/en
Publication of ITUB20160876A1 publication Critical patent/ITUB20160876A1/it
Priority to IL260893A priority patent/IL260893B2/en
Priority to CL2018002196A priority patent/CL2018002196A1/es
Priority to US18/096,165 priority patent/US20230172904A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
ITUB2016A000876A 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo ITUB20160876A1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITUB2016A000876A ITUB20160876A1 (it) 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo
JP2018543132A JP2019505542A (ja) 2016-02-19 2017-02-17 ヒトにおける軸性近視の予防／阻止に使用するための抗アレルギー薬とムスカリン性アンタゴニストおよび／またはドパミン作動薬との組み合わせ
AU2017220640A AU2017220640B2 (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
KR1020187026872A KR20180117642A (ko) 2016-02-19 2017-02-17 인간에서 축성 근시를 예방/중단하는데 사용하기 위한 무스카린성 길항제 및/또는 도파민성 작용제를 갖는 항알레르기제의 배합물
CN201780011993.4A CN108883060A (zh) 2016-02-19 2017-02-17 用于预防/阻止人轴性近视的抗过敏剂与毒蕈碱拮抗剂和/或多巴胺能激动剂的组合
CA3013846A CA3013846A1 (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
US15/999,784 US20200253951A1 (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
PCT/EP2017/053619 WO2017140846A1 (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
SG11201806599SA SG11201806599SA (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
BR112018016845A BR112018016845A2 (pt) 2016-02-19 2017-02-17 combinação de um agente antialérgico com um antagonista muscarínico e/ou um agonista dopaminérgico para uso na prevenção/suspensão de miopia axial em humanos
EP17710482.5A EP3416617A1 (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
RU2018133026A RU2793238C2 (ru) 2016-02-19 2017-02-17 Применение бензтропина с целью остановки прогрессирования аксиальной миопии у человека
SG10202007417SA SG10202007417SA (en) 2016-02-19 2017-02-17 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
IL260893A IL260893B2 (en) 2016-02-19 2018-07-31 A combination of an anti-allergic agent with a muscarinic antagonist and/or a dopaminergic agonist for use in the prevention/termination of axial myopia in humans
CL2018002196A CL2018002196A1 (es) 2016-02-19 2018-08-09 Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos.
US18/096,165 US20230172904A1 (en) 2016-02-19 2023-01-12 Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000876A ITUB20160876A1 (it) 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Publications (1)

Publication Number Publication Date
ITUB20160876A1 true ITUB20160876A1 (it) 2017-08-19

Family

ID=55948995

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A000876A ITUB20160876A1 (it) 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Country Status (13)

Country Link
US (2) US20200253951A1 (it)
EP (1) EP3416617A1 (it)
JP (1) JP2019505542A (it)
KR (1) KR20180117642A (it)
CN (1) CN108883060A (it)
AU (1) AU2017220640B2 (it)
BR (1) BR112018016845A2 (it)
CA (1) CA3013846A1 (it)
CL (1) CL2018002196A1 (it)
IL (1) IL260893B2 (it)
IT (1) ITUB20160876A1 (it)
SG (2) SG11201806599SA (it)
WO (1) WO2017140846A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
KR20230051130A (ko) * 2020-06-02 2023-04-17 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 선택적 히스타민 h1-수용체 길항제인 레보카바스틴 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
CN114558069A (zh) 2022-04-06 2022-05-31 杭州美依生物科技有限公司 一种眼部舒缓涂抹液及其制备方法
CN115137314B (zh) * 2022-09-02 2022-11-15 首都医科大学附属北京同仁医院 近视风险评估方法、装置及穿戴设备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090170A1 (en) * 2010-12-30 2012-07-05 Enable Innovations S.P.A. Products for ophtalmic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033246T2 (de) 1989-06-21 1999-12-02 Univ Pennsylvania Behandlung und Regulierung der Augenentwicklung mit cholinergischen Agonisten
CA2567981C (en) 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
CA2594741A1 (en) 2005-01-14 2006-07-20 Schering Corporation Synthesis of himbacine analogs
BRPI0714587A2 (pt) * 2006-07-25 2013-05-07 Osmotica Corp suluÇço oftÁlmica aquosa e uso da nesna
SG151148A1 (en) * 2007-10-05 2009-04-30 Singapore Health Services Pte Method and/or kit for determining response to muscarinic receptor antagonist treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090170A1 (en) * 2010-12-30 2012-07-05 Enable Innovations S.P.A. Products for ophtalmic use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUDREY CHIA ET AL: "Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 119, no. 2, 20 July 2011 (2011-07-20), pages 347 - 354, XP028395893, ISSN: 0161-6420, [retrieved on 20110725], DOI: 10.1016/J.OPHTHA.2011.07.031 *
DEL CUVILLO ET AL: "Allergic Conjunctivitis and H 1 Antihistamines", J INVESTIG ALLERGOL CLIN IMMUNOL, 1 January 2009 (2009-01-01), pages 11 - 18, XP055308704, Retrieved from the Internet <URL:http://www.jiaci.org/issues/vol19s1/3.pdf> [retrieved on 20161009] *
LUFT W A ET AL: "Variable effects of previously untested muscarinic receptor antagonists on experimental myopia", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE - IOVS, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 44, no. 3, 1 March 2003 (2003-03-01), pages 1330 - 1338, XP002315956, ISSN: 0146-0404, DOI: 10.1167/IOVS.02-0796 *
MARTÍN ANDREA P ET AL: "The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study", BMC OPHTHALMOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 3, no. 1, 6 January 2003 (2003-01-06), pages 2, XP021016312, ISSN: 1471-2415, DOI: 10.1186/1471-2415-3-2 *
PREMA GANESAN ET AL: "Pharmaceutical intervention for myopia control", EXPERT REVIEW OF OPHTHALMOLOGY, vol. 5, no. 6, 9 December 2010 (2010-12-09), GB, pages 759 - 787, XP055308425, ISSN: 1746-9899, DOI: 10.1586/eop.10.67 *

Also Published As

Publication number Publication date
SG11201806599SA (en) 2018-09-27
RU2018133026A3 (it) 2020-04-24
CL2018002196A1 (es) 2019-01-25
WO2017140846A1 (en) 2017-08-24
US20230172904A1 (en) 2023-06-08
IL260893B1 (en) 2023-04-01
KR20180117642A (ko) 2018-10-29
JP2019505542A (ja) 2019-02-28
AU2017220640A1 (en) 2018-10-04
US20200253951A1 (en) 2020-08-13
IL260893A (it) 2018-09-20
IL260893B2 (en) 2023-08-01
AU2017220640B2 (en) 2022-08-25
BR112018016845A2 (pt) 2018-12-26
CN108883060A (zh) 2018-11-23
EP3416617A1 (en) 2018-12-26
SG10202007417SA (en) 2020-09-29
RU2018133026A (ru) 2020-03-19
CA3013846A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ITUB20160876A1 (it) Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l&#39;uso in prevenzione/ arresto di miopia assiale nell’uomo
ZA201901113B (en) Anti¿tim¿3 antibodies and use thereof
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
DK3502667T3 (da) Lysdetekteringsanordninger med beskyttende foring og metoder i forbindelse med samme
ES2784639T8 (es) Uso combinado de un vector que codifica un receptor modificado y su agonista exógeno en el tratamiento de convulsiones
IT201700072994A1 (it) Sistema plurisensoriale adattato per la prevenzione di malattie professionali nell’ambiente di lavoro, e metodo per l’uso del sistema
IL280827A (en) Alpha 4 integrin antagonists and preparations containing them for use in the treatment of ocular disorders
ZA202000443B (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
SG11201704756YA (en) Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
IT201600068623A1 (it) “use of a lignin fraction as an anti-phytopathogenic agent and anti-phytopathogenic compositions comprising the same” / “uso di una frazione di lignina come agente antifitopatogenico e composizioni antifitopatogeniche che la comprendono”
MA47290A (fr) Combinaison d&#39;un agoniste sélectif de l&#39;il-2rbeta et d&#39;un agoniste de l&#39;il-15 à action prolongée
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
IT201700081272A1 (it) Indumento per uso in operazioni di spegnimento di incendi e simili
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell&#39;apparato cardiovascolare
MA43114A (fr) Formulation combinée à dose fixe d&#39;éflornithine et sulindac
ITUA20161865A1 (it) Uso di lentinano per il trattamento e la prevenzione di endometriosi.
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
FR3023003B1 (fr) Combinaison synergique de biomarqueurs pour la detection et l&#39;evaluation d&#39;une fibrose hepatique
IT201700109607A1 (it) Composizione per l&#39;uso nella prevenzione e/o nel trattamento del glaucoma.
IT201700104655A1 (it) Dispositivo indossabile per la fornitura di materiali e/o strumenti per la ricostruzione dentale.
IT201600130706A1 (it) 4 amino-2-pirido-biciclo pirimidine e lo uso come medicamenti
IT201700076508U1 (it) Barriera multifunzione divisoria ed antiabbagliamento ad alta sostenibilita&#39; economica
UA33433S (uk) Інтерфейс головної сторінки сайту «ria.com» (2.0.)
IT201700056680A1 (it) Composizione per l’uso nella prevenzione e nel trattamento della disfunzione erettile.
GB201902087D0 (en) Medicament and the use thereof